Clinical trials: Excitatory Amino Acid Agents
Schizophrenia
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
This application seeks renewed support for MH59803, "Dopaminergic substrates of startle gating across species," to extend a clear path of "bench-to-bedside" progress towards a critical paradigm shift in therapeutic models for…
- Trial name
- NCT02634684
- Testing
- Dextroamphetamine
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
Ketamine Infusions for PTSD and Treatment-Resistant Depression
The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning.
- Trial name
- NCT02577250
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Autistic Disorder
Safety and Effectiveness of D-Cycloserine in Children With Autism
This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.
- Trial name
- NCT00198120
- Testing
- D-cycloserine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Indiana University
Suicide, Depressive Disorder, Treatment-Resistant
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action
- Trial name
- NCT06511908
- Testing
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Mental Health (NIMH)
Behavioral Symptoms, Suicide
Natural History of Depression, Bipolar Disorder and Suicide Risk
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments.
- Conditions
- Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents
- Trial name
- NCT06462196
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression, Major Depressive Disorder
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine
- Trial name
- NCT05615948
- Testing
- VTS-K
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Theresa Jacob, PhD, MPH
Depression, Unipolar
Repeated Neurocognitive Measurements in Depressed Patients
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning…
- Trial name
- NCT05991232
- Testing
- Intravenous Ketamine
- Where
- United States
- Sponsor
- Jay Fournier
Post-Traumatic Stress Disorders, Major Depressive Disorder
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability.
- Trial name
- NCT04032301
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Autistic Disorder
Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.
- Trial name
- NCT00198107
- Testing
- Aripiprazole, D-cycloserine
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Indiana University